Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Authors
Keywords
IDO, Immunotherapy, Nivolumab, Kynurenine, Anti-PD-1
Journal
Journal of Translational Medicine
Volume 16, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-06
DOI
10.1186/s12967-018-1595-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma
- (2018) Andreas Seeber et al. CANCER SCIENCE
- Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non–Small Cell Lung Carcinoma Tumors
- (2018) Edwin Roger Parra et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy
- (2017) Yuan Wang et al. OncoTargets and Therapy
- Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients
- (2016) M.F. Sanmamed et al. ANNALS OF ONCOLOGY
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Targeting key dioxygenases in tryptophan–kynurenine metabolism for immunomodulation and cancer chemotherapy
- (2015) Christopher J.D. Austin et al. DRUG DISCOVERY TODAY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding the role of the kynurenine pathway in human breast cancer immunobiology
- (2015) Benjamin Heng et al. Oncotarget
- Association of Leukocyte Mitochondrial DNA Copy Number with Colorectal Cancer Risk: Results from the Shanghai Women's Health Study
- (2014) B. Huang et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation
- (2014) W. Chen et al. JOURNAL OF IMMUNOLOGY
- The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress
- (2013) F. Sahm et al. CANCER RESEARCH
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells
- (2009) D. J. Chung et al. BLOOD
- Immune escape as a fundamental trait of cancer: focus on IDO
- (2008) G C Prendergast ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started